Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy

Overview

About this study

The purpose of this study is to evaluate the effect of intravitreal faricimab or fluocinolone acetonide (FAc) intravitreal implant compared with observation on long-term visual acuity following treatment of choroidal melanoma with iodine-125 plaque brachytherapy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Key Inclusion Criteria:

- Primary uveal melanoma (excluding iris melanoma) receiving primary treatment with
plaque brachytherapy

- Absence of unrelated cause of visual loss

- Baseline visual acuity ≥ 34 letters (20/200 Snellen equivalent or better)

- Posterior tumor margin >0 mm from the center of the macula (i.e., tumor is NOT under
the geometric center of the fovea)

- Posterior tumor margin >0 mm from the closest disc margin (i.e., tumor is not touching
the edge of the optic disc)

- Calculated total dose to center of the macula ≥30 Gy

Key Exclusion Criteria:

- Opaque media

- Inability to undergo fluorescein angiography

- Less than 18 years of age

- Prior vitrectomy

- Intraocular pressure (IOP) ≥ 25 mmHg or history of steroid- induced IOP elevation that
required treatment at baseline

- IOP ≥ 25 mmHg at randomization or increase in IOP ≥ 8 mmHg from baseline to
randomization (following steroid challenge

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 7/20/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Lauren Dalvin, M.D.

Open for enrollment

Contact information:

Suzanne Wernimont CCRP

(507) 538-8119

Wernimont.Suzanne@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20558479

Mayo Clinic Footer